rs3859865
Variant names:
Variant summary
Our verdict is Benign. The variant received -12 ACMG points: 0P and 12B. BP4_StrongBA1
The NM_032608.7(MYO18B):c.40-914G>A variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.207 in 152,176 control chromosomes in the GnomAD database, including 3,349 homozygotes. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
Frequency
Genomes: 𝑓 0.21 ( 3349 hom., cov: 33)
Consequence
MYO18B
NM_032608.7 intron
NM_032608.7 intron
Scores
2
Clinical Significance
Not reported in ClinVar
Conservation
PhyloP100: -0.676
Publications
4 publications found
Genes affected
MYO18B (HGNC:18150): (myosin XVIIIB) The protein encoded by this gene may regulate muscle-specific genes when in the nucleus and may influence intracellular trafficking when in the cytoplasm. The encoded protein functions as a homodimer and may interact with F actin. Mutations in this gene are associated with lung cancer. [provided by RefSeq, Jul 2008]
MYO18B Gene-Disease associations (from GenCC):
- Klippel-Feil anomaly-myopathy-facial dysmorphism syndromeInheritance: AR Classification: DEFINITIVE, STRONG, MODERATE, SUPPORTIVE Submitted by: Labcorp Genetics (formerly Invitae), Orphanet, Ambry Genetics, ClinGen, G2P
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -12 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.82).
BA1
GnomAd4 highest subpopulation (AFR) allele frequency at 95% confidence interval = 0.226 is higher than 0.05.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MYO18B | ENST00000335473.12 | c.40-914G>A | intron_variant | Intron 2 of 43 | 1 | NM_032608.7 | ENSP00000334563.8 | |||
MYO18B | ENST00000407587.6 | c.40-914G>A | intron_variant | Intron 2 of 43 | 1 | ENSP00000386096.2 | ||||
MYO18B | ENST00000536101.5 | c.40-914G>A | intron_variant | Intron 2 of 42 | 1 | ENSP00000441229.1 | ||||
MYO18B | ENST00000539302.5 | n.40-914G>A | intron_variant | Intron 1 of 41 | 1 | ENSP00000437587.1 |
Frequencies
GnomAD3 genomes AF: 0.207 AC: 31496AN: 152056Hom.: 3338 Cov.: 33 show subpopulations
GnomAD3 genomes
AF:
AC:
31496
AN:
152056
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
We have no GnomAD4 exomes data on this position. Probably position not covered by the project.
GnomAD4 genome AF: 0.207 AC: 31526AN: 152176Hom.: 3349 Cov.: 33 AF XY: 0.204 AC XY: 15166AN XY: 74414 show subpopulations
GnomAD4 genome
AF:
AC:
31526
AN:
152176
Hom.:
Cov.:
33
AF XY:
AC XY:
15166
AN XY:
74414
show subpopulations
African (AFR)
AF:
AC:
9554
AN:
41516
American (AMR)
AF:
AC:
2804
AN:
15302
Ashkenazi Jewish (ASJ)
AF:
AC:
925
AN:
3466
East Asian (EAS)
AF:
AC:
631
AN:
5172
South Asian (SAS)
AF:
AC:
660
AN:
4822
European-Finnish (FIN)
AF:
AC:
1740
AN:
10594
Middle Eastern (MID)
AF:
AC:
63
AN:
294
European-Non Finnish (NFE)
AF:
AC:
14553
AN:
67988
Other (OTH)
AF:
AC:
436
AN:
2112
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.501
Heterozygous variant carriers
0
1288
2575
3863
5150
6438
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Alfa
AF:
Hom.:
Bravo
AF:
Asia WGS
AF:
AC:
428
AN:
3478
ClinVar
Not reported inComputational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.